BPC-157 human studies: what has been measured in people

Five human studies of BPC-157 exist. Two were reported only as conference abstracts and never published as full papers. The three that were published had no control group and 31 participants between them ¹.

That is the whole human record for a compound sold on the strength of tendon, ligament and muscle repair. FDA found the same five studies when it reviewed BPC-157 in 2026, searching PubMed, Embase, the Cochrane Database of Systematic Reviews, its own safety reporting systems and ClinicalTrials.gov ¹. Four more trials are registered and none has posted results ^{2 3 4 5}.

The one trial that measured whether it worked

A multicentre, randomised, double-blind, placebo-controlled phase 2 study randomised 53 people with mild to moderate ulcerative colitis 1 to an 80 mg enema of BPC-157, then under the development code PL 14736, once daily for two weeks, or to placebo. 46 of them completed. The primary endpoint was change in a disease activity index, which the authors described only as a composite of clinical, laboratory, endoscopic and pathohistological findings ¹.

The mean change was -3.2 points with BPC-157 (95 percent confidence interval -5.58 to -0.82) and -1.6 points with placebo (95 percent confidence interval -3.86 to 0.67), an estimated between-group difference of 1.6 points with a confidence interval from -4.84 to 1.62 ¹.

That last interval is the finding. It is the range of true differences the data are compatible with, and it includes zero: the trial's own numbers fit a modest benefit, no difference at all, and placebo doing better. A difference that could as easily be zero has not been shown.

The sentence most often quoted from this trial is the authors' own summary, that PL 14736 "was very well tolerated and safe"; the efficacy result sits in the same abstract and is quoted far less. FDA's verdict was that "the data presented for this study are therefore inadequate to support the efficacy and safety of BPC-157 given as an enema for two weeks for the treatment of UC" ¹.

The phase 1 study, and the measurement that failed

The other randomised study was a placebo-controlled phase 1 tolerability and pharmacokinetic study in healthy volunteers, reported as abstracts in 2002 and 2003. 32 people were randomised and 24 received BPC-157 by enema. Headache and flatulence were the most frequent adverse events, with "no obvious difference in frequency or severity after PL 14736 and placebo dosing" ¹.

Its pharmacokinetic half returned nothing: BPC-157 was not detected in plasma, and in the 2003 abstract most concentrations fell below the assay's lower limit of quantification. This study is also an unindexed meeting abstract, readable only through FDA's account of it ¹.

Three published reports, 31 people, no comparison groups

A retrospective chart review at one private clinic found 17 people given BPC-157 by injection into the knee for mixed knee complaints. 16 were reached by telephone 6 months to 1 year later and 14 reported significant improvement in pain: 11 of the 12 given BPC-157 alone, and 3 of the 4 given it with thymosin beta-4. The authors note that "no specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living" ⁶.

A single-arm pilot treated 12 women with interstitial cystitis, aged 39 to 76, who had not responded to pentosan polysulfate, an approved therapy. Each had BPC-157 injected into the bladder wall around the inflamed area during one cystoscopy. Ten reported complete resolution and rated the result 100 percent; the other two rated it 80 percent, about a fifth of their symptoms remaining. All 12 scored 5 out of 5 on the Global Response Assessment, the study's single patient-rated endpoint ⁷.

The third report infused two people, both of whom had been receiving intravenous BPC-157 before they enrolled, with 10 mg on one day and 20 mg the next. Their cardiac, liver, kidney, thyroid and glucose markers did not change across three days of blood panels and questioning, and neither reported a symptom. The authors concluded that "the results of this pilot study showed the safety of BPC-157 in humans" ⁸. Two prior users watched for three days cannot show that.

All three were run at private clinics in Florida, all three appeared in the same journal, and all three share an author. That is a fact about the evidence base rather than a criticism of anyone: the three human data points behind most consumer claims are not independent.

Four registered trials, none reporting

A phase 1 pharmacokinetic study was registered in 2015, with an estimated enrolment of 42 healthy volunteers and primary completion estimated for February 2016. Its record has not been updated since December 2015 and its status is recorded as unknown, so whether it ever dosed anyone is not public. No results are posted, and FDA searched in December 2025 and was unable to find an associated published study ^{2 1}.

Two trials are now designed to measure whether BPC-157 does anything to a human soft-tissue injury, and both are randomised and blinded. A phase 2 trial in acute grade II hamstring strain is recruiting an estimated 120 participants, with MRI-assessed injury volume at day 14 among its primary outcomes and primary completion estimated for February 2027 ³. A phase 1 trial in an estimated 30 patients recovering from rotator cuff repair surgery, with shoulder strength as its primary outcome, was not yet recruiting and has an estimated start of January 2027 ⁴. The hamstring trial started first, in February 2026, and is the only one of the two using imaging.

The fourth, completed in 40 participants, tested a supplement gummy over eight weeks against blood markers of inflammation and self-reported swelling. It is single group: no randomisation, no placebo, no masking, and no posted results ⁵. An uncontrolled supplement study cannot establish an anti-inflammatory effect.

What the one systematic review made of it

The only systematic review of BPC-157 in orthopaedic sports medicine screened 544 articles and included 36. Thirty-five of them were preclinical. The one clinical study was the knee chart review ⁹.

The review also reports that study with a different number: 7 of 12 patients relieved for more than 6 months, where the paper reports 11 of 12 improving in the group given BPC-157 alone ^{9 6}. Those may not be the same quantity. The paper asked patients how long the relief lasted, so the review's figure may be the subset whose relief passed six months, a narrower question than whether pain improved at all. The full text is paywalled, so which of the two it is cannot be settled here. It is worth knowing that the single clinical study in this literature reaches a reader as two different numbers depending on which paper reports it.

The documented human safety record

FDA searched its adverse event reporting system through December 2025 and retrieved three reports, all for injected BPC-157: injection-site redness and swelling in a 55-year-old woman who was also injecting compounded thymosin, shortness of breath leading to an emergency room visit in a 28-year-old man, and diffuse hyperpigmentation with darkening of the gums in a 40-year-old woman using a product that contained both BPC-157 and TB-500 ¹⁰.

A separate search of FDA's complaint system for foods, dietary supplements and cosmetics, run through December 2025, returned three further cases. FDA notes that assessing all of them was complicated by BPC-157 being taken as part of a multi-ingredient dietary supplement ¹.

Spontaneous reports cannot establish cause, and FDA notes that pharmacies compounding under section 503A generally do not report adverse events to it, so these are floors rather than counts. In the published literature there is nothing: FDA identified no case report of BPC-157 ¹.

What the record adds up to

FDA's two conclusions after reviewing all of it were that "there is a lack of evidence to support the effectiveness" of either form of BPC-157 for ulcerative colitis, the indication it evaluated, and that "there is insufficient clinical safety information to characterize the safety profile" ¹.

Whether BPC-157 changes the healing of an injured tendon, ligament or muscle in a person has not been measured. What has been measured, in 17 people at one clinic with no comparison group, is whether they said their knee hurt less months afterwards. Those are different questions, and only the first is the one the compound is sold on. The hamstring trial is the first built to answer it and will not report before 2027. Until then the honest answer is not that BPC-157 works, and not that it does not: nobody has looked properly.